Cargando…

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB

New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been associated with improved outcomes in the treatment of drug-resistant tuberculosis, but that success is threatened by emerging drug resistance. We report a case of bedaquiline and delamanid resistance in a 55-year-ol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Millard, James, Rimmer, Stephanie, Nimmo, Camus, O’Donnell, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124645/ https://www.ncbi.nlm.nih.gov/pubmed/37081529 http://dx.doi.org/10.3201/eid2905.221716

Ejemplares similares

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis
por: Nimmo, Camus, et al.
Publicado: (2020)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: an individual isolate metaanalysis
por: Nimmo, Camus, et al.
Publicado: (2023)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid
por: Nieto Ramirez, Luisa Maria, et al.
Publicado: (2020)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
por: Kambili, C., et al.
Publicado: (2022)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Erratum: Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid: A Prospective Multicountry Study
Publicado: (2021)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )
por: Huerga, Helena, et al.
Publicado: (2022)

Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature
por: Traoré, Afsatou Ndama, et al.
Publicado: (2022)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vojpipr41uo8ddft1t9aaoqh5k